NCAM1 and ganglioneuroma: Six out of eleven ganglioneuroma and ganglioneuroblastoma species had no reactivity against PSA-NCAM, while higher-stage ganglioneuroma and some ganglioneuroblastoma samples had moderate to high reactivity (25).